Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 7/20 | 0.53 |
| ▸ | CDK2 | P24941 | 6/20 | 0.53 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.52 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.52 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.52 |
| ▸ | CDK4 | P11802 | 3/20 | 0.48 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.48 |
| ▸ | CDK9 | P50750 | 4/20 | 0.47 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.47 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.47 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.47 |
| ▸ | AURKA | O14965 | 1/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
| ▸ | MET | P08581 | 1/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.47 |
| ▸ | FLT1 | P17948 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4737275 | 0.84 | PIK3CA (0.52) | GSK3BCDK2PIK3CGPIK3CAPIK3CB | |
| SCHEMBL4738430 | 0.82 | PIK3CG (0.69) | GSK3BCDK2PIK3CGPIK3CAPIK3CB | |
| SCHEMBL4736832 | 0.81 | PIK3CG (0.65) | GSK3BCDK2PIK3CGPIK3CAPIK3CB | |
| SCHEMBL13279745 | 0.76 | TBK1 (0.54) | GSK3BCDK2PIK3CGPIK3CAPIK3CB | |
| SCHEMBL4733401 | 0.75 | ABL1 (0.60) | GSK3BCDK2PIK3CGPIK3CAPIK3CB | |
| SCHEMBL4735908 | 0.74 | PIK3CG (0.69) | CDK2PIK3CGPIK3CAPIK3CBDYRK1A | |
| SCHEMBL1032946 | 0.73 | PIK3CA (0.60) | GSK3BCDK2PIK3CGPIK3CAPIK3CB | |
| SCHEMBL12801339 | 0.73 | CDK2 (0.59) | GSK3BCDK2PIK3CGPIK3CAPIK3CB | |
| SCHEMBL4386288 | 0.73 | SYK (0.70) | CDK2SYK | |
| SCHEMBL4734845 | 0.73 | CDK9 (0.63) | GSK3BCDK2PIK3CGPIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080153822-A1 | Methods of treating pain | INGENIUM PHARMACEUTICALS GMBH (DE) | 2008-06-26 | — | — | US | claimed |
| WO-2008065155-A1 | CDK INHIBITORS FOR TREATING PAIN | INGENIUM PHARMACEUTICALS GMBH (DE) | 2008-06-05 | — | — | WO | claimed |
| US-20070021419-A1 | 2-Aminophenyl-4-phenylpyrimidines as kinase inhibitors | CYCLACEL LIMITED (GB) | 2007-01-25 | — | — | US | claimed |
| JP-2007500179-A | — | — | 2007-01-11 | — | — | JP | claimed |
| EP-1648875-A1 | 2-AMINOPHENYL-4-PHENYLPYRIMIDINES AS KINASE INHIBITORS | Cyclacel Limited (GB) | 2006-04-26 | — | — | EP | claimed |
| WO-2005012262-A1 | 2-AMINOPHENYL-4-PHENYLPYRIMIDINES AS KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2005-02-10 | — | — | WO | claimed |
| US-20080153822-A1 | Methods of treating pain | INGENIUM PHARMACEUTICALS GMBH (DE) | 2008-06-26 | — | — | US | disclosed |
| WO-2008065155-A1 | CDK INHIBITORS FOR TREATING PAIN | INGENIUM PHARMACEUTICALS GMBH (DE) | 2008-06-05 | — | — | WO | disclosed |
| US-20070021419-A1 | 2-Aminophenyl-4-phenylpyrimidines as kinase inhibitors | CYCLACEL LIMITED (GB) | 2007-01-25 | — | — | US | disclosed |
| US-20070021419-A1 | 2-Aminophenyl-4-phenylpyrimidines as kinase inhibitors | CYCLACEL LIMITED (GB) | 2007-01-25 | — | — | US | disclosed |
| US-20070021419-A1 | 2-Aminophenyl-4-phenylpyrimidines as kinase inhibitors | CYCLACEL LIMITED (GB) | 2007-01-25 | — | — | US | disclosed |
| EP-1648875-A1 | 2-AMINOPHENYL-4-PHENYLPYRIMIDINES AS KINASE INHIBITORS | Cyclacel Limited (GB) | 2006-04-26 | — | — | EP | disclosed |
| WO-2005012262-A1 | 2-AMINOPHENYL-4-PHENYLPYRIMIDINES AS KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2005-02-10 | — | — | WO | disclosed |
| WO-2005012262-A1 | 2-AMINOPHENYL-4-PHENYLPYRIMIDINES AS KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021419-A1 | 2-Aminophenyl-4-phenylpyrimidines as kinase inhibitors | GRK3, NCOR1, GRM3 | GSK3B 2240/4885CDK2 342/4885PIK3CG 1548/4885 |
| US-20080153822-A1 | Methods of treating pain | OPRL1, ACHE, OPRK1 | GSK3B 2287/4885CDK2 4427/4885PIK3CG 4311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.